drugset
drugset / Trial / NCT02544152

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

NCT02544152 ↗

Phase 2 Terminated 71 enrolled Sucampo Pharma Americas, LLC Sucampo AG · collabTakeda · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.

Timeline

Start
2015-02
Primary completion
2016-12
Completion
2016-12

Outcome

Missed primary endpoint

registry analysis (other test); Placebo vs Lubiprostone; p =0.9870; Cochran-Mantel-Haenszel NCT02544152 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 8 ug Oral

Indications

irritable bowel syndrome